We are live on ! Find out more
Primecap Management

Primecap Management Portfolio holdings

AUM $127B
1-Year Est. Return 44.11%
This Fund
S&P 500
This Quarter Est. Return
-0.26%
1 Year Est. Return
+44.11%
3 Year Est. Return
+121.64%
5 Year Est. Return
+154.22%
10 Year Est. Return
+724.54%
AUM
$102B
AUM Growth
-$731M
Cap. Flow
+$803M
Cap. Flow %
0.79%
Top 10 Hldgs %
35.47%
Holding
263
New
6
Increased
107
Reduced
91
Closed
3

Top Buys

Rank Stock Value
1
BABA icon
Alibaba
BABA
+$347M
2
JPM icon
JPMorgan Chase
JPM
+$285M
3
NTAP icon
NetApp
NTAP
+$279M
4
TRCO
TRIBUNE MEDIA COMPANY CLASS A
TRCO
+$225M
5
HPQ icon
HP
HPQ
+$142M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$585M
2
CME icon
CME Group
CME
+$258M
3
HON icon
Honeywell
HON
+$194M
4
DTV
DIRECTV COM STK (DE)
DTV
+$131M
5
INTU icon
Intuit
INTU
+$117M

Sector Composition

Rank Sector Weight
1 Healthcare 28.73%
2 Technology 26.95%
3 Industrials 13.34%
4 Consumer Discretionary 8.18%
5 Financials 6.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NUVA
176
DELISTED
NuVasive, Inc.
NUVA
$42.7M 0.04%
901,000
PEP icon
177
PepsiCo
PEP
$189B
$42M 0.04%
450,000
EW icon
178
Edwards Lifesciences
EW
$51.5B
$39.9M 0.04%
1,680,000
LVS icon
179
Las Vegas Sands
LVS
$29.9B
$39.4M 0.04%
750,000
CERS icon
180
Cerus
CERS
$468M
$38.4M 0.04%
7,400,000
+100,000
+1% +$474K
GUID
181
DELISTED
Guidance Software, Inc.
GUID
$37.7M 0.04%
4,451,707
SZYM
182
DELISTED
SOLAZYME INC COM STK (DE)
SZYM
$37.6M 0.04%
11,972,209
+80,500
+0.7% +$276K
ACLS icon
183
Axcelis
ACLS
$4.2B
$36.5M 0.04%
3,085,500
VA
184
DELISTED
Virgin America Inc.
VA
$31.7M 0.03%
1,154,900
+1,111,293
+2,548% +$32.2M
DD
185
DELISTED
Du Pont De Nemours E I
DD
$31.1M 0.03%
511,653
+3,686
+0.7% +$248K
SSYS icon
186
Stratasys
SSYS
$760M
$30.9M 0.03%
885,000
+240,000
+37% +$10.1M
SYK icon
187
Stryker
SYK
$129B
$28.2M 0.03%
295,500
NWL icon
188
Newell Brands
NWL
$2.56B
$26.2M 0.03%
638,060
+375,000
+143% +$15M
CAM
189
DELISTED
CAMERON INTERNATIONAL CORPORATION
CAM
$26.2M 0.03%
500,200
-130,000
-21% -$6.74M
UTIW
190
DELISTED
UTI WORLDWIDE INC
UTIW
$25.8M 0.03%
2,581,000
+136,000
+6% +$1.31M
ABUS icon
191
Arbutus Biopharma
ABUS
$897M
$24.7M 0.02%
2,080,000
+1,531,397
+279% +$23.3M
CSTM icon
192
Constellium
CSTM
$3.88B
$23.8M 0.02%
2,014,500
-17,600
-0.9% -$277K
CRM icon
193
Salesforce
CRM
$153B
$22.1M 0.02%
317,460
CIR
194
DELISTED
CIRCOR International, Inc
CIR
$22M 0.02%
403,500
-8,000
-2% -$442K
DBD
195
DELISTED
Diebold Nixdorf Incorporated
DBD
$19.7M 0.02%
562,000
XOOM
196
DELISTED
XOOM CORP COM
XOOM
$19.6M 0.02%
928,800
-611,000
-40% -$11.4M
NNBR icon
197
NN Inc
NNBR
$298M
$19.3M 0.02%
755,000
+37,800
+5% +$994K
MATV icon
198
Mativ Holdings
MATV
$644M
$19.2M 0.02%
481,200
MBLY
199
DELISTED
Mobileye N.V.
MBLY
$17.6M 0.02%
330,650
HA
200
DELISTED
Hawaiian Holdings, Inc.
HA
$17.6M 0.02%
740,000
+15,000
+2% +$350K

Similar funds

Primecap Management's Q2 2015 Portfolio in Review

As of Q2 2015, Primecap Management held 263 positions worth $102B, down 0.71% from $102B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Trading was light in Q2 2015: portfolio turnover was 3.4%. Primecap Management opened 6 new positions and exited 3, leaving the 263-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, up from 28% a quarter earlier, followed by Technology and Industrials.

  • Primecap Management's largest Q2 2015 buy was Pfenex Inc.: 2,371,388 shares worth $46M.
  • Primecap Management added most to Alibaba in Q2 2015, an estimated $347M increase.
  • Primecap Management's biggest Q2 2015 reduction was CME Group, cutting an estimated $258M.
  • Primecap Management fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $585M.
  • Primecap Management's ten largest holdings make up 35% of its $102B portfolio in Q2 2015.
  • Primecap Management opened 6 new positions and closed 3 in Q2 2015.
  • Primecap Management's portfolio value fell 0.71% quarter-over-quarter to $102B.

Based on Primecap Management's 13F filing for Q2 2015, filed 13 Aug 2015.